Tech Company Financing Transactions

OncoMed Pharmaceuticals Funding Round

OncoMed Pharmaceuticals, based in Redwood City, raised $154 million from Adams Harkness Ventures, Bay Partners and De Novo Ventures.

Transaction Overview

Company Name
OncoMed Pharmaceuticals
Announced On
11/4/2008
Transaction Type
Venture Equity
Amount
$154,000,000
Round
Undisclosed
Investors

Adams Harkness Ventures (Terry Gould)

Bay Partners (Atul Kapadia)

De Novo Ventures (Frederick Dotzler)

GlaxoSmithKline

Latterell Venture Partners (James Woody)

Morgenthaler Ventures (James Broderick)

The Vertical Group (Jack Lasersohn)

U.S. Venture Partners (Jonathan Root)

Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
800 Chesapeake Dr.
Redwood City, CA 94063
USA
Phone
(650) 995-8200
Website
www.oncomed.com
Email Address
[email protected]
Overview
OncoMed Pharmaceuticals (NASDAQ: OMED) is discovering and developing monoclonal antibodies and small molecules capable of destroying cancer stem cells, a recently discovered type of cell believed to seed the growth of cancers and underlie cancer's ability to spread and take root in tissues.
Profile
OncoMed Pharmaceuticals LinkedIn Company Profile
Social Media
OncoMed Pharmaceuticals Company Twitter Account
Company News
OncoMed Pharmaceuticals News
Facebook
OncoMed Pharmaceuticals on Facebook
YouTube
OncoMed Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
John Lewicki
  John Lewicki LinkedIn Profile  John Lewicki Twitter Account  John Lewicki News  John Lewicki on Facebook
Chief Scientific Officer
Austin Gurney
  Austin Gurney LinkedIn Profile  Austin Gurney Twitter Account  Austin Gurney News  Austin Gurney on Facebook
Vice President
Ann Kapoun
  Ann Kapoun LinkedIn Profile  Ann Kapoun Twitter Account  Ann Kapoun News  Ann Kapoun on Facebook
VP - Finance
Yvonne Li
  Yvonne Li LinkedIn Profile  Yvonne Li Twitter Account  Yvonne Li News  Yvonne Li on Facebook
VP - General Counsel
Alicia Hager
  Alicia Hager LinkedIn Profile  Alicia Hager Twitter Account  Alicia Hager News  Alicia Hager on Facebook
VP - R & D
Robert Stagg
  Robert Stagg LinkedIn Profile  Robert Stagg Twitter Account  Robert Stagg News  Robert Stagg on Facebook
VP - Regulatory Affairs
Jill Henrich
  Jill Henrich LinkedIn Profile  Jill Henrich Twitter Account  Jill Henrich News  Jill Henrich on Facebook

 

 

Browse more venture capital transactions:

Prev: 11/4/2008: ServiceMax venture capital transaction
Next: 11/5/2008: Arbor Photonics venture capital transaction

 

Share this article

 

News on VC Transactions

We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.